Nasus Pharma Ltd.报告财年业绩

2026-03-25 21:17

Nasus Pharma Ltd. press release (NSRX): FY Cash, Cash Equivalents and Marketable Securities: As of December 31, 2025, Nasus had cash, cash equivalents and marketable securities of $4.3 million, compared with cash and cash equivalents of $0.3million as of December 31, 2024.
For the year ended December 31, 2025, net loss was $5.9 million compared with a net loss of $1.5 million for the year ended December 31, 2024.
"Following our $15 private placement, which closed in February 2026, Nasus expects that its cash, cash equivalents and marketable securities will be sufficient to fund its operations through the second quarter of 2027."

More on Nasus Pharma Ltd.